Factors determining the therapeutic window for stroke

Neurology

Volumn 50, Issue 3, 1998, Pages 599-603

  Zivin, Justin A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOLYTIC AGENT; NEUROPROTECTIVE AGENT; TISSUE PLASMINOGEN ACTIVATOR;

BRAIN INJURY; BRAIN ISCHEMIA; CLINICAL TRIAL; DISEASE DURATION; DRUG CONTRAINDICATION; DRUG EFFICACY; EMERGENCY TREATMENT; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; SPINAL CORD ISCHEMIA; STATISTICAL ANALYSIS; STROKE; TRANSIENT ISCHEMIC ATTACK;

EID: 0031895572     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.50.3.599     Document Type: Review

References (20)

1. Siesjö BK. Brain energy metabolism. New York: John Wiley & Sons, 1978.
2. Brain Resuscitation Clinical Trial I Study Group. Randomized clinical study of thiopental loading in comatose survivors of cardiac arrest. N Engl J Med 1986;314:397-403.
3. Toole JF. The Willis Lecture: transient ischemic attacks, scientific method, and new realities. Stroke 1991;22:99-104.
4. Zivin JA, Waud DR. Quantal bioassay and stroke. Stroke 1992;23:767-773.
5. De Lean A, Munson PJ, Rodbard D. Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves. Am J Physiol 1978;235:E97-E102.
6. Aronowski J, Ostrow P, Samways E, Strong R, Zivin JA, Grotta JC. Graded bioassay for demonstration of brain rescue from experimental acute ischemia in rats. Stroke 1994;25: 2235-2240.
7. Drummond JC. Brain protection during anesthesia. Anesthesiology 1993;79:877-880.
8. Warner DS, McFarlane C, Todd MM, Ludwig P, McAllister AM. Sevoflurane and halothane reduce focal ischemic brain damage in the rat. Anesthesiology 1993;79:985-992.
9. Pulsinelli WA, Brierley JB. A new model of bilateral hemispheric ischemia in the unanesthetized rat. Stroke 1979;10: 267-272.
10. Jones TH, Morawetz RB, Crowell RM, et al. Thresholds of focal cerebral ischemia in awake monkeys. J Neurosurg 1981; 54:773-782.
11. Clark WM, Madden KP, Rothlein R, Zivin JA. Reduction of central nervous system ischemic injury in rabbits using leukocyte adhesion antibody treatment. Stroke 1991;22:877-883.
12. Weinstein PR, Anderson GG, Telles DA. Neurological deficit and cerebral infarction after temporary middle cerebral artery occlusion in unanesthetized cats. Stroke 1986;17:318-324.
13. Pulsinelli WA, Levy DE, Duffy TE. Regional cerebral blood flow and glucose metabolism following transient forebrain ischemia. Ann Neurol 1982;11:500-509.
14. Zivin JA, DeGirolami U. Studies of the influence of biogenic amines on central nervous system ischemia. Stroke 1986;17: 509-516.
15. The Ancrod Stroke Study Investigators. Ancrod for the treatment of acute ischemic brain infarction. Stroke 1994;25:1755-1759.
16. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-1587.
17. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: the European Cooperative Stroke Study (ECASS). JAMA 1995;274:1017-1025.
18. Donnan GA, Davis SM, Chambers BR, et al. Streptokinase for acute ischemic stroke with relationship to time of administration. JAMA 1996;276:961-966.
19. The Multicenter Acute Stroke Trial - Europe Study Group. Thrombolytic therapy with streptokinase in acute ischemic stroke. N Engl J Med 1996;335:145-150.
20. Multicentre Acute Stroke Trial - Italy (MAST-I) Group. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Lancet 1995;346:1509-1514.